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Purpose
Patients with sickle cell disease (SCD) in Africa have a
high risk of premature death, mainly due to insufficient
medical services. Some SCD patients in the first author’s
clinic experienced symptomatic improvement after
administration of biofield therapy. The objective of this
study was to evaluate the effectiveness of biofield ther-
apy for SCD patients over a 4-year period.
Methods
We adopted Okada Purifying Therapy (OPT) as an inter-
v e n t i o ni nt h i ss t u d y .W ef o r m e dag r o u po f2 0S C D
patients aged 3-36 years (OPT group), and a control group
(n=20) of a matching age/gender profile from regular
patients at the clinic. OPT was administered by certified
practitioners approved by MOA International Corporation
(http://www.moainternational.or.jp/) every weekday for
one year. We examined participating patients’ blood tests
at the beginning and end of the 1-year period and ran a
follow-up survey after 4 years.
Results
During the 1-year study period, the OPT group showed a
significant improvement in the blood data: hemoglobin
[median value from 6.3g/dl (25-75 percentile: 6.1-7.2) to
10.1g/dl (9.4-11.1), p<0.001], total bilirubin [from 9.3mg/dl
(6.5-9.4) to 3.2mg/dl (2.2-4.1), p<0.001], and creatinine
[from 1.1mg/dl (0.9-1.7) to 0.7mg/dl (0.6-0.8), p<0.001].
The control group had less improvement in hemoglobin
[from 6.3g/dl (6.0-7.0) to 7.1g/dl (6.4-7.9), p=0.015] and
total bilirubin [from 9.1mg/dl (6.8-9.3) to 6.8mg/dl (6.2-
7.6), p=0.004] than the OPT group (p<0.001); creatinine
increased from 0.9mg/dl (0.8-1.1) to 1.2mg/dl (1.0-1.5)
(p<0.001). Three patients in the OPT group and all of the
control group needed hospitalization once or more
(p<0.001). After 4 years, 17 in the OPT group and 13 in
the control group survived (p=0.27).
Conclusion
Considering the insufficient medical services, biofield
therapy has possibly contributed to the positive out-
comes, although the care given by the practitioners may
also have had some influences. In conclusion, biofield
therapy is considered safe and effective for SCD patients
with various symptoms.
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